Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777623 | 0.93 | PLA2G2A (0.46) | PLA2G2ATLR7ALDH1A1KDM4EALOX15 | |
| SCHEMBL3780495 | 0.88 | PTGDR2 (0.48) | PLA2G2AKDM4EL3MBTL1NPSR1LMNA | |
| SCHEMBL3772821 | 0.87 | ALDH1A1 (0.40) | PLA2G2ATLR7ALDH1A1KDM4EALOX15 | |
| SCHEMBL3777108 | 0.83 | ALDH1A1 (0.44) | PLA2G2ATLR7ALDH1A1KDM4EALOX15 | |
| SCHEMBL3777107 | 0.80 | KDM4E (0.46) | PLA2G2AKDM4ENPSR1LMNASMN1; SMN2 | |
| SCHEMBL3781729 | 0.80 | ALDH1A1 (0.41) | PLA2G2ATLR7ALDH1A1KDM4EALOX15 | |
| SCHEMBL3344656 | 0.79 | TP53 (0.41) | ALDH1A1KDM4EALOX15MAPK1L3MBTL1 | |
| SCHEMBL27743397 | 0.79 | PLA2G2A (0.41) | PLA2G2ATLR7ALDH1A1KDM4EALOX15 | |
| SCHEMBL27826430 | 0.78 | PLA2G2A (0.42) | PLA2G2AALDH1A1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL3788414 | 0.78 | RORC (0.41) | PLA2G2AALDH1A1KDM4EL3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| CN-101316591-B | Quinoline compound and pharmaceutical application thereof | ARGENTA ORAL THERAPEUTICS LTD. (GB) | 2012-02-01 | — | — | CN | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| CN-101316591-A | Quinolines and their therapeutic use | ARGENTA DISCOVERY LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | PLA2G2A 1779/4885TLR7 116/4885ALDH1A1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.